Investors

 

We take seriously the trust our shareholders place in us to deliver on our mission. Explore our earnings reports, investor events and stock information to learn more about our commitment to global healthcare.

Last Updated:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News

Apr. 15, 2024
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Learn more
Apr. 1, 2024
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
Learn more
Mar. 27, 2024
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
Learn more
Explore press releases

Events & presentations

March 27, 2024
at 10:00 AM EDT
Go to webcast
February 28, 2024
at 8:30 AM EST
Browse all events
Show all

Fourth Quarter 2023 Financial Results

Featured Documents

Our Leaders

Our leaders

 
Our seasoned executive management team and board of directors bring decades of expertise, knowledge and strategic vision to Viatris.
Meet our leaders

Corporate governance

 
Viatris is a publicly traded company that is managed and controlled under the oversight of the company’s board of directors. Learn more about the guidelines, committee charters and other documents that describe our corporate governance framework.
Learn more

Corporate responsibility

 
As we work to help patients live healthier at every stage of life, we continue to advance responsible and sustainable operations, recognizing that our actions affect the stakeholders and communities we serve.
Learn more

FAQs

 
Browse our list of questions frequently asked by investors or reach out to our team for more information about Viatris.
Investor-related FAQs

Email Alerts

Contact Us

LinkedIn